

Amendments to the Claims.

Please amend the claims to read as follows:

1. (Currently Amended) A method of induction of particular amyloid plaques, the method comprising the steps of:

- a) immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a selected medium by allowing SGAG to air dry on the selected medium;
- b) adding to the immobilized SGAG on the medium a quantity of dissolved low fibrillar A β 1-40 (LFA β), and
- c) ~~whereby spherical amyloid plaques are formed that demonstrate a Maltese-cross pattern when stained with Congo Red and viewed under polarized light.~~
- c) staining with Congo Red, and
- d) viewing under polarized light,

whereby spherical amyloid plaques are formed that demonstrate a Maltese-cross pattern.

2. (Original) The method of Claim 1, wherein the LFA β is added in a A β :SGAG weight/weight (w/w) ratio range of between 1:0.01 to 1:20.
3. (Original) The method of Claim 2, wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.1 to 1:10.
4. (Original) The method of Claim 3, wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.5 to 1:2.

5. (Original) The method of Claim 4, wherein the LFA β is added in a A β :SGAG w/w ratio of about 1:1.
6. (Original) The method of Claim 1, wherein the selected medium is either a slide, a film or a titer well plate.
7. (Original) The method of Claim 1, wherein the SGAG is selected from the group of SGAGs consisting of heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate, and the GAG-related macromolecule is dextran sulfate.
8. (Previously presented) The method of Claim 6, wherein the titer well plate is an 18 - 96 well PTFE fluoropolymer partitioned slide.
9. (Cancelled)
10. (Currently Amended) A method of induction of particular amyloid plaques, the method comprising the steps of:
 - a) immobilizing a quantity of a sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a PTFE fluoropolymer partitioned slide well and allowing SGAG to air dry in the PTFE fluoropolymer partitioned slide well, the SGAG selected from the group of SGAGs consisting of heparin, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate, and the GAG-related macromolecule is dextran sulfate;
 - b) adding to the immobilized SGAG on the slide well a quantity of dissolved low fibrillar A β 1-40 (LFA β), wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.5 to 1:2 by bubbling the LFA β into the slide well, and

- e) ~~whereby spherical amyloid plaques are formed that demonstrate a~~
~~Maltese cross pattern when stained with Congo Red and viewed under~~
~~polarized light.~~

c) staining with Congo Red, and

d) viewing under polarized light,

whereby spherical amyloid plaques are formed that demonstrate a Maltese-cross
pattern.

11- 32. (Cancelled)

33. (Previously presented) The method of claim 1 or 10, where the SGAG and LFA β are incubated at about 25 to 40°C.

34. (Previously presented) The method of claim 33, where incubation occurs at 37°C.

35. (Previously presented) The method of claim 33, where incubation occurs for about 12 to 24 hours.

AMENDMENT TO SPECIFICATION

Please insert the following sentence at the end of the first paragraph of the Patent Specification on page 1. Before the paragraph heading entitled "Technical Field":

This invention was made with Government support under 1R43 AG017018 awarded by the National Institute on Aging. The Government has certain rights in the invention.